Overcoming upstream and downstream process barriers for large scale AAV production
Sponsor
Given the broad treatment potential and demonstrated efficacy of recently approved viral vector-based gene therapies, there is an established need for reproducible and consistent manufacturing solutions that yield high titer, high quality viral particles for clinical applications. It is critical to implement a robust manufacturing process that addresses the upstream and downstream production challenges of obtaining sufficient titers and purity for in vivo applications, while also meeting safety and regulatory requirements for clinical use.
We bring together industry and commercial perspectives to discuss key barriers to address clinical needs and market supply of gene therapies. Hear experts from Thermo Fisher Scientific and Encoded Therapeutics explore solutions to overcome these issues and provide a practical example of implementation. Gain valuable insights and strategies to optimize your AAV manufacturing processes and accelerate the development of safe and effective gene therapies.
- Find out about an end-to-end solution for development and commercial production of AAV
- Learn how new products and technologies can help address production efficiency, regulatory concerns, and scale-up of AAV production protocols
- Understand how critical manufacturing challenges are currently being addressed by gene therapy developers
SPEAKERS
You might also like
Achieving cost effective, scalable high-titer AAV production
Hit the lentiviral characterization jackpot with accurate RNA detection
Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic
Biological & operational considerations for iPSC-derived cell production
